Trial Designed to Test Hepatitis B Vaccine Timing
Researchers plan to compare birth-dose vaccination against the standard six-week schedule for newborns in Guinea-Bissau.
Updated on Oct. 11, 2026 in Babies
Live Poll
Should researchers use local standards of care for clinical trials in low-income countries?
The University of Southern Denmark has approved a study of 14,000 newborns to evaluate the health outcomes of receiving the hepatitis B vaccine at birth versus the current national six-week schedule. The trial is funded by the Centers for Disease Control and Prevention, though it awaits final authorization from the government of Guinea-Bissau.
Why it matters
The study aims to determine the optimal timing for hepatitis B vaccination in a country where 12% of adults live with chronic infection. Chronic hepatitis B, which affects 90% of infants infected at birth, is a major cause of cirrhosis and liver cancer, making effective prevention strategies a significant public health priority.
This clinical trial will randomize 14,000 newborns to receive either a hepatitis B birth dose or follow the current national schedule beginning at 6 weeks. While the World Health Organization recommends birth doses, this study seeks to clarify the vaccination outcomes within the local context.
The players
Centers for Disease Control and Prevention
A U.S. federal agency that protects public health by providing critical scientific information and funding for disease prevention initiatives.
University of Southern Denmark
A research-focused educational institution that approved the study protocol for the Bandim Health Project.
Peter Aaby
A lead researcher at the Bandim Health Project investigating vaccination schedules and pediatric health outcomes.
Christine Stabell Benn
A lead researcher at the Bandim Health Project focusing on vaccine efficacy and the impact of early immunization protocols.
World Health Organization
A specialized agency of the United Nations responsible for international public health, including immunization standards.
The details
The trial protocol involves administering the hepatitis B vaccine alongside existing tuberculosis and polio vaccination programs. Researchers will assess how early immunization affects long-term health, as roughly 90% of infants infected at birth develop chronic hepatitis B. By testing the efficacy of a birth dose compared to the current six-week delay, the team aims to refine prevention strategies for a region where chronic infection remains a persistent health burden.
Timeline
February 2026: WHO issued a statement regarding the planned trial.
Summer 2026: A revised protocol was approved by the Guinea-Bissau ethics committee.
October 2026: The University of Southern Denmark approved the study.
2028: Guinea-Bissau plans to introduce a formal hepatitis B birth dose policy.
Health Landscape
This trial is part of the long-term research efforts conducted by the Bandim Health Project in Guinea-Bissau. It sits within a broader effort to reduce the 12% adult chronic hepatitis B prevalence by optimizing infant vaccination schedules.
This research focuses on population-level data and does not change individual vaccination recommendations, which should always be discussed with your pediatrician. Parents in endemic regions should monitor local public health updates regarding the planned 2028 birth dose policy rollout.
The takeaway
The study highlights the critical importance of early prevention in reducing the long-term risk of chronic liver disease. Discuss any concerns regarding your child's immunization schedule with your physician to ensure they remain protected according to current national health standards.
Further reading
For more information on newborn health and early immunization guidelines, explore our Babies section.
Source note: This article includes information reported by Medical Daily.
Live Poll
Should researchers use local standards of care for clinical trials in low-income countries?
